Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Lenvatinib in Advanced Solid Tumors
NCT05014828Phase 2Completed
- Sponsor
- BeiGene
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC), gastric cancer (GC), renal cell carcinoma (RCC), urothelial carcinoma (UC), sponsored by BeiGene. Started Sep 2021; status: completed.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)gastric cancer (GC)renal cell carcinoma (RCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05014828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014828.